Replimune Group, Inc. Share Price & Technical Analysis
REPL · $4.88 (-0.61%)
Healthcare / Biotechnology
$4.88
-0.61%
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP …
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
96% return in May, -4% avg return in past 3 year May month.
17% return in 2026, 3% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -29% | 12% | 4% | -66% | 96% | – | – | – | – | – | – | – | 17% |
| 25 | 13% | -7% | -23% | 1% | -8% | 0% | -25% | -21% | -24% | 137% | 6% | -3% | 47% |
| 24 | -8% | 10% | -6% | -23% | -17% | 70% | 11% | 2% | 8% | 8% | 22% | -14% | 63% |
| 23 | 1% | -22% | -20% | -5% | 13% | 22% | -9% | -3% | -17% | -14% | -22% | -24% | -100% |
| 22 | -27% | -20% | 6% | -2% | -13% | 20% | 10% | 0% | -8% | 6% | 10% | 33% | 14% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$346.80M
P/E ratio
—
52W high
$13.24
52W low
$1.50
Volume
2,58,934
Beta
0.12
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Replimune Group, Inc. share price today?
- Replimune Group, Inc. (REPL) last traded around $4.88 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does REPL have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for REPL. Download the app for real-time alerts.
- How can I analyze Replimune Group, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.